May 22, 2020 -- Clinical-stage biopharmaceutical company IMV has announced that it is moving forward with a vaccine against the novel coronavirus to test in clinical trials.
The company first studied immunogenic and antibody responses to 23 peptide epitopes in preclinical trials before selecting multiple peptides for its vaccine candidate, DPX-COVID-19. The vaccine is intended to work through multiple mechanisms to prevent infection and inhibit the virus from entering cells.
Vaccine development remains on schedule, and IMV plans to conduct a phase I clinical study this summer. The company is also performing vaccination-challenge preclinical assays in animal models with the intent to publish results later this year.